Citius Oncology, Inc. (CTOR)

Market Cap	79.15M
Revenue (ttm)	n/a
Net Income (ttm)	-19.52M
Shares Out	71.30M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,222
Open	1.110
Previous Close	1.110
Day's Range	1.020 - 1.115
52-Week Range	0.850 - 49.000
Beta	-0.21
Analysts	Strong Buy
Price Target	4.50 (+305.41%)
Earnings Date	Dec 24, 2024

About CTOR

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2021
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: CTOR

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 2 analysts, the average rating for CTOR stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 305.41% from the latest price.

Price Target

$4.5

(305.41% upside)

Analyst Consensus: Strong Buy